Cortigent (VANI)

Executive Summary

Cortigent is a privately held neurostimulation company developing targeted systems to restore communication between the brain and specific body parts, aiming to help patients regain function lost to disease or injury. Founded in 2021 and headquartered in Sylmar, California, the company leverages advanced neuromodulation technology to bypass damaged neural pathways. Its platform focuses on improving motor control and sensory feedback for conditions such as stroke, spinal cord injury, and other neurological disorders, with the potential to address significant unmet needs in rehabilitation and assistive medicine. While specific product details and clinical pipelines are not publicly disclosed, Cortigent's valuation of approximately $105 million and its listing under the ticker VANI suggest it is positioned for growth in the medical device space. The company's strategy likely involves pursuing FDA approvals for initial indications, expanding into additional applications, and forming partnerships to scale commercialization. Given the early-stage nature and competitive landscape, execution on regulatory and clinical milestones will be critical to unlocking value.

Upcoming Catalysts (preview)

• Q1 2027FDA Approval for Upper Limb Motor Recovery Indication40% success
• Q3 2026Initiation of Pivotal Trial for Second Indication (e.g., Bladder Control)70% success
• Q2 2026Strategic Partnership or Licensing Deal with Major MedTech Company30% success